Business Context and Reporting Period
Company: PMGC Holdings Inc. (formerly Elevai Labs Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2026
Reporting Period: Event date February 4, 2026
Business Context: PMGC Holdings Inc., through its wholly owned subsidiary Northstrive Biosciences Inc., entered into a definitive License Agreement with Modulant Biosciences LLC. The agreement grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize licensed products in the field of non-human animal health (including feed additives) worldwide, excluding the Republic of Korea.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data for the reporting period.
- Revenue/Profit/Cash Flow: Not provided in this filing.
- Debt/Liquidity: Not provided in this filing.
- Transaction Consideration: Modulant agreed to pay Northstrive Biosciences a percentage of "IP Revenue" (including upfront payments, milestones, and royalties) until a specific aggregate "Threshold Amount" is reached. Upon reaching this threshold, the revenue-share rate decreases to a lower percentage. Specific dollar amounts for the threshold or percentages are redacted or not disclosed in the text summary.
Material Changes Versus Prior Period
The filing reports the execution of a binding License Agreement on February 4, 2026, which formalizes terms previously outlined in a binding term sheet dated May 12, 2025 (reported in a prior Form 8-K on May 16, 2025). This represents a material change in the company's intellectual property commercialization strategy, establishing a new revenue stream via royalties and revenue sharing from Modulant's commercialization efforts in the animal health sector.
Guidance, Outlook, and Risks
Management Commentary and Outlook
The agreement positions Northstrive Biosciences to monetize its intellectual property in the non-human animal health field without direct commercialization responsibilities, relying on Modulant to use "Commercially Reasonable Efforts" to develop and commercialize at least one licensed product.
Risks and Contingencies
- Scope Limitation: The license explicitly excludes human use, human clinical trials, and human pharmaceutical development.
- Territorial Exclusion: The Republic of Korea is excluded from the licensed territory; Northstrive retains rights there.
- Termination Risks: The agreement may be terminated for material breach (with a 60-day cure period) or immediately upon bankruptcy/insolvency proceedings. Upon termination due to Modulant's breach, Northstrive receives a perpetual, royalty-free license to Modulant's interest in new IP.
- Liability: Liability for special, consequential, or indirect damages is limited, except for indemnification obligations, confidentiality breaches, or gross negligence/willful misconduct.
- Dependency: The rights granted are conditioned upon the terms of the "Head License" under which Northstrive obtained the IP.
Investor Verification Checklist
- Verify the specific "Threshold Amount" and the exact revenue-share percentages before and after the threshold, as these figures are redacted in the summary text.
- Review the full text of the "Head License" to understand upstream obligations that condition the rights granted to Modulant.
- Confirm the status of the "Licensed Patents" listed in Exhibit A of the full agreement to assess the strength and duration of the IP portfolio.
- Monitor Modulant's progress in meeting the "Commercially Reasonable Efforts" obligation to develop at least one licensed product.
- Check for any subsequent filings regarding the "Excluded Territory" (Republic of Korea) to see if separate commercialization plans exist for that region.